Neuberger Berman Group
PLX icon

Neuberger Berman Group’s Protalix BioTherapeutics PLX Stock Holding History

Neuberger Berman Group’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27K Sell
11,580
-49
-0.4% -$104 ﹤0.01% 2316
2026
Q1 		$25.2K Buy
+11,629
New +$28.9K ﹤0.01% 2139
2018
Q3 		– Sell
-1,495
Closed -$6K – 1684
2018
Q2 		$6K Buy
+1,495
New +$6.64K ﹤0.01% 1699

Other funds holding PLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Neuberger Berman Group's PLX Position: Q2 2026 in Review

Neuberger Berman Group reduced its Protalix BioTherapeutics (PLX) stake by 0.42% in Q2 2026, selling an estimated $104 and leaving 11,580 shares worth $27K. The position accounts for ﹤0.01% of the portfolio, ranked #2316.

Neuberger Berman Group first reported a position in PLX in Q2 2018 and has held it in 3 quarters since. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

  • Neuberger Berman Group held 11,580 shares of Protalix BioTherapeutics worth $27K as of Q2 2026.
  • Neuberger Berman Group sold 49 Protalix BioTherapeutics shares in Q2 2026, an estimated $104.
  • Protalix BioTherapeutics made up ﹤0.01% of Neuberger Berman Group's portfolio in Q2 2026, its #2316 holding.
  • Neuberger Berman Group first reported a position in Protalix BioTherapeutics in Q2 2018 and has held it in 3 quarters since.
  • 102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.